Takeda Pharmaceutical Company Limited (TAK)
| Previous Close | 14.82 |
| Open | 14.79 |
| Bid | 14.72 x 1800 |
| Ask | 14.73 x 3100 |
| Day's Range | 14.71 - 14.81 |
| 52 Week Range | 12.58 - 16.39 |
| Volume | |
| Avg. Volume | 2,155,925 |
| Market Cap | 46.708B |
| Beta (5Y Monthly) | 0.50 |
| PE Ratio (TTM) | 44.65 |
| EPS (TTM) | 0.33 |
| Earnings Date | Oct 31, 2024 |
| Forward Dividend & Yield | 0.58 (3.94%) |
| Ex-Dividend Date | Mar 27, 2024 |
| 1y Target Est | 17.04 |
BloombergBuyout Firm GTCR Is in Advanced Talks to Acquire German Drugmaker Stada
(Bloomberg) -- Buyout firm GTCR is in advanced talks on a potential acquisition of German generic drugmaker Stada Arzneimittel AG, people with knowledge of the matter said. Most Read from BloombergHow Americans Voted Their Way Into a Housing CrisisAfter a Record Hot Summer, Pressure Grows for A/C MandatesChicago Halts Hiring as Deficit Tops $1 Billion Through 2025UC Berkeley Gives Transfer Students a Purpose-Built Home on CampusFor Tenants, AI-Powered Screening Can Be a New Barrier to HousingGTC
Insider MonkeyTakeda Pharmaceutical Company Limited (TAK): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Short Sellers. In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the other cheap pharmaceutical stocks. The pharmaceutical industry is one of the most interesting sectors to invest in. This is […]
Business WireTakeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
OSAKA, Japan & CAMBRIDGE, Mass., August 07, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADZYNMA®▼ (recombinant ADAMTS13) for the treatment of ADAMTS13 deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cTTP).3 ADZYNMA is now the first and only enzyme replacement therapy in the European Union (EU) specifically for the treatment of cTTP.3,4 This approval includes confirmation of orphan medicinal product des
